The combination of adoptive cell therapy (ACT) with tumour infiltrating lymphocytes (TIL) and checkpoint inhibitors (CPI) appear to show promise in heavily pretreated patients with a range of solid cancers. A Danish study, published in the Journal for Immunotherapy of Cancer, comprised 25 adults with metastatic disease across 10 solid cancer types including colon cancer ...
TIL-based ACT regimes show promise in a range of solid cancers
By Mardi Chapman
7 Oct 2021